Novartis : Novartis ESG call feedback (Buy, TP CHF97.0): the integration of corporate responsibility into the group’s strategy is even clearer under the aegis of the new CEO
>On 14 August, Novartis announced the appointment of Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer. He will be a member of the executive committee and will report to Vas Narasimhan, the group’s CEO – he is expected to take up his position in December 2018. This appointment augurs well since, for the first time, the Chief Ethics Risk and Compliance Officer will be a member of the group’s executive committee, reflecting the strategic importance of the...Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.